We describe a new antibody, called anti-glial nuclear antibody (AGNA), in patients with paraneoplastic neurological syndromes (PNS) and small-cell lung carcinoma (SCLC). AGNA was initially identified in 24 sera of our archives by immunohistochemistry on rat cerebellum. AGNA positive sera showed a characteristic nuclear staining of the Bergmann glia in the Purkinje cell layer. Immunoblots and probing a cerebellar expression library with AGNA sera did not identify the antigen. Twenty of the 24 patients with AGNA had PNS and all but two had lung cancer. AGNA was identified in 13 / 113 (11.5%) patients with SCLC compared with 0 / 122 with other types of cancer ( p < 0.0001). The frequency of AGNA was not higher than expected for the presence of SCLC in the different PNS subtypes except in LEMS ( p = 0.0002). AGNA was present in 13 / 30 (43%) of LEMS patients with SCLC, compared with 0 / 19 of LEMS patients without cancer ( p = 0.0006). We conclude that the recognition of AGNA is helpful since this antibody is found in PNS associated with SCLC, particularly LEMS, in which other onconeural antibodies are absent. D
Introduction
The detection of onconeural antibodies has been very useful in helping to define the paraneoplastic etiology of a given neurological syndrome. Onconeural antibodies are detected in many laboratories by screening of sera on frozen sections of rat or mouse cerebellum (Moll et al., 1995; Vincent et al., 1998) . Positive immunoreactivities are usually confirmed by immunoblot of recombinant proteins or neuronal homogenates.
Sera from patients with small-cell lung carcinoma (SCLC), the most common tumor associated with paraneoplastic neurological syndromes (PNS), sometimes harbor antibodies against neural antigens that have not previously been recognized as associated with PNS (Gure et al., 2000) . When this happens, it is important first to establish whether the antibody is related to the presence of a specific type of cancer, and second to investigate whether the antibody is associated with a particular PNS. Even if the antibody is not directly related to the immune response that causes a PNS, it may indicate the presence of an underlying cancer undiagnosed at the time of the antibody determination.
Here we describe a new antibody specificity, and show that it is a marker for SCLC. This antibody may help in the diagnosis of SCLC-related PNS, particularly the Lambert -Eaton myasthenic syndrome (LEMS).
